{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-23-000004","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2023-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.766616+00:00","generated_at":"2026-06-18T04:45:34.527662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tarsus reports FY2022 net loss of $62.1M; PDUFA for TP-03 on Aug 25, 2023","bullets":["Full-year net loss $62.1M vs $13.8M in 2021; revenue from TP-03 out-license was $25.8M.","Cash, cash equivalents and marketable securities $217.0M; runway into at least 2H 2026.","TP-03 NDA accepted; PDUFA target action date August 25, 2023 for Demodex blepharitis.","Completed enrollment of Ersa Phase 2a (MGD); topline data expected H2 2023.","Initiated Galatea Phase 2a trial of TP-04 for rosacea; Phase 1 safety supported progression."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-23-000004","json":"https://secwatch.observer/filing/0001819790-23-000004.json","markdown":"https://secwatch.observer/filing/0001819790-23-000004.md","text":"https://secwatch.observer/filing/0001819790-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000004/0001819790-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000004/tars-20230313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T04:45:34.527662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19c41dbe964a5486e813418512d389f6f45c48c1","claim":"Tarsus Pharmaceuticals, Inc. reported the full-year ended December 31, 2022 results: revenue $25.8 million.","evidence_excerpt":"blepharitis ● TP-03 Topline Phase 2a (Ersa) Meibomian Gland Disease ● Full-Year 2022 Financial Results • Full year TP-03 out-license revenue for greater China territory was $25.8 million, compared to $57.0 million in 2021 • Full year net loss was $62.1 million, compared to $13.8 million in 2021 • Full year research and development expenses were $42.6 million,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000004/0001819790-23-000004-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full-year ended December 31, 2022"},{"label":"Revenue","value":"$25.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}